SAGE 241220 5.00C (SAGE241220C5000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

SAGE241220C5000

Watchlist

0.52
+0.12+30.00%

15min DelayClose Dec 20 16:00 ET

0.52High0.20Low

Intraday

5D
Daily

News

As Small-caps Ride the Trump Wave, Here Are the Best & Worst Such Stocks as per SA Quant
Seeking AlphaDec 17 13:16 ET
Sage Therapeutics Price Target Cut to $6.00/Share From $10.00 by Stifel
Dow JonesDec 16 08:24 ET · Ratings
Sage Therapeutics Analyst Ratings
BenzingaDec 16 08:12 ET · Ratings
Stifel Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Cuts Target Price to $6
Moomoo NewsDec 16 07:34 ET · Ratings
Express News | Sage Therapeutics Inc : Mizuho Cuts Target Price to $6 From $10
ReutersDec 12 06:48 ET
Mizuho Securities Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Announces Target Price $10
Moomoo NewsDec 12 02:33 ET · Ratings

Comments

Jaguar8

Oct 17 06:42

NEWS

$Sage Therapeutics (SAGE.US)$
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
Sage Therapeutics has announced a strategic reorganization to support the launch of ZURZUVAE for postpartum depression and focus on pipeline development. The plan includes a workforce reduction of approximately 33%, affecting over 165 employees. This restructuring aims to extend the company's cash runway and position it for long-term ...

Jaguar8

Oct 8 05:31

NEWS

$Sage Therapeutics (SAGE.US)$
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
Sage Therapeutics (Nasdaq: SAGE) announced topline results from the Phase 2 LIGHTWAVE Study of dalzanemdor (SAGE-718) in treating mild cognitive impairment and mild dementia in Alzheimer's Disease. The study did not demonstrate a statistically significant difference from basel...

Sikander KHAN

Jul 29 08:26

Don't expect exceptional Q2 results.

$Sage Therapeutics (SAGE.US)$ Stock is good, but sentiment is negative. I don't see any significant and sustainable upside by Q3. Another 20% to 30% downside is 'Likely'
My research and analysis are not advice or recommendations. It's for information and knowledge purposes only. Any research , analysis, information, or other material received should not be construed as individualized investment advice. Investment decisions should be made as part of financial ...

Trytosaveabit

Jul 24 05:39

Update

$Sage Therapeutics (SAGE.US)$ Sage Therapeutics Inc: Sage-324 (Biib124) Did Not Demonstrate a Statistically Significant Dose-Response Relationship on Primary Endpoint

_easymoneysniper_

Jun 11 06:16

$Sage Therapeutics (SAGE.US)$ what just happened